Titan Pharmaceuticals announced Kate DeVarney, Ph.D., Executive Vice President and Chief Scientific Officer, has been elected to the Company's Board of Directors.
Dr. DeVarney, a clinical neuropsychologist by training, joined Titan in January 2007 and spearheaded the development of Probuphine® (buprenorphine) implant, the first six-month long acting product approved in the United States, Canada and Europe for the treatment of opioid use disorder in eligible patients. Prior to joining Titan, she served as Senior Director at Corcept Therapeutics and as Senior Medical Director for Neurosciences within World Wide Human Health at Merck & Co. Dr. DeVarney also held positions within the Neurosciences research and development and medical affairs organizations of SmithKline Beecham and GlaxoSmithKline. Throughout her academic and industry careers, Dr. DeVarney's research has focused primarily on addiction; neurodegenerative disorders, including Alzheimer's disease and Parkinson's disease; mood and anxiety disorders; metabolic disorders and obesity.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!
"Kate's leadership of the clinical development and medical affairs team at Titan is greatly valued by all, and we welcome her as a Board member and look forward to her future contributions to the growth of the company," said Titan's Executive Chairman, Dr. Marc Rubin. "I would like to take this opportunity to thank Dr. Rajinder Kumar, who retired from the Board in December, for his contributions to Titan over the past several years, and wish him the best in his future endeavors."